Arabic Arabic English English French French German German

Drugs used by some Type 2 diabetics may lessen their risk for severe COVID-19 complications

A type of drug already used to treat obesity and Type 2 diabetes, when taken six months prior to the diagnosis of COVID-19, was associated with a decreased risk of hospitalization, respiratory complications and death in COVID-19 patients with Type 2 diabetes, according to researchers at Penn State College of Medicine. The team, which analyzed electronic medical records of patients with type 2 diabetes, concluded that the drugs, called glucagon-like peptide-1 receptor (GLP-1R) agonists, should be further evaluated for potential protective effects against COVID-19 complications. Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Q&A: Children and storm anxiety

Next Post

Hungry or full: It comes down to the atomic details

Related Posts